6.2. primary carcinoma situ. without treatment, approximately 54% patients cis progress muscle-invasive disease (le: 3). reliable prognostic factors, studies, however, reported worse prognosis concurrent cis t1 tumours compared primary cis , extended cis cis prostatic urethra . response intravesical treatment bcg chemotherapy important prognostic factor subsequent progression death caused bc . approximately 10 20% complete responders eventually experience disease progression muscle-invasive disease, compared 66% non- responders .